GRFS Grifols SA IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1438569 · Reporting currency EUR
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 | FY20202020-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 7.21B | 6.59B | 6.06B | 4.93B | 5.34B |
| Cost of revenue | 4.42B | 4.11B | 3.85B | 2.97B | 3.08B |
| Gross profit | 2.79B | 2.48B | 2.21B | 1.96B | 2.26B |
| R&D expense | 384.04M | 395.28M | 361.14M | 354.88M | 294.22M |
| SG&A expense | 1.26B | 1.37B | 1.20B | 1.06B | 985.62M |
| Operating income | 1.19B | 782.32M | 782.44M | 595.06M | 996.13M |
| Interest expense | 714.76M | 596.88M | 478.32M | 267.70M | 249.64M |
| Pretax income | 444.00M | 207.02M | 338.01M | 350.45M | 878.63M |
| Income tax | 231.19M | 43.35M | 90.11M | 85.13M | 169.64M |
| Net income | 156.92M | 42.32M | 185.03M | 188.73M | 618.55M |
| EBITDA | 1.63B | 1.23B | 1.19B | 954.83M | 1.32B |
| EPS (basic) | 0.23 | 0.06 | 0.27 | 0.28 | 0.90 |
| EPS (diluted) | 0.23 | 0.06 | 0.27 | 0.28 | 0.90 |
| Weighted avg. shares (diluted) | 679.92M | 677.10M | 679.29M | 681.40M | 685.14M |
| Balance sheet | |||||
| Cash & equivalents | 979.78M | 529.58M | 549.21M | 2.68B | 579.65M |
| Receivables | 835.60M | 767.26M | 739.04M | 499.71M | 520.16M |
| Inventory | 3.56B | 3.48B | 3.24B | 2.26B | 2.00B |
| Current assets | 5.73B | 6.13B | 4.69B | 5.51B | 3.16B |
| PP&E, netmay include right-of-use assets (IFRS) | 3.34B | 3.25B | 3.30B | 2.55B | 2.32B |
| Goodwill | 7.40B | 6.80B | 7.01B | 6.23B | 5.33B |
| Intangibles | 2.93B | 2.83B | 2.95B | 1.64B | 1.56B |
| Total assets | 21.41B | 20.99B | 21.23B | 19.23B | 15.27B |
| Current liabilities | 2.16B | 2.33B | 2.02B | 3.47B | 1.34B |
| Short-term debt | 318.20M | 674.31M | 449.41M | 127.89M | 169.56M |
| Long-term debt | 2.34B | 3.65B | 3.59B | 3.58B | 3.30B |
| Total debt | 2.66B | 4.32B | 4.04B | 3.71B | 3.46B |
| Total liabilities | 12.80B | 13.48B | 13.25B | 11.92B | 8.55B |
| Shareholders' equity | 5.88B | 5.37B | 5.65B | 5.52B | 5.11B |
| Net debt | 1.68B | 3.79B | 3.49B | 1.03B | 2.89B |
| Cash flow statement | |||||
| Operating cash flow | 902.17M | 218.69M | -1.43M | 596.98M | 1.11B |
| Capital expenditure | 232.54M | 224.44M | 283.80M | 247.37M | 280.15M |
| Free cash flow | 669.63M | -5.75M | -285.23M | 349.60M | 830.18M |
| Investing cash flow | 886.67M | -394.72M | -2.00B | -854.15M | -858.12M |
| Financing cash flow | -1.36B | 171.49M | -164.90M | 2.30B | -354.40M |
| Depreciation & amortization | 437.90M | 446.42M | 410.98M | 359.77M | 321.53M |
| Dividends paid | 962,000 | 0 | 592,000 | 258.95M | 113.23M |
| Share buybacks | — | 0 | 3.46M | 125.70M | — |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.